EAACI Leadership Reflects on Record-Breaking Congress 2025: A Pivotal Moment for Allergy and Immunology
'This year's Congress was a turning point,' said Prof. Maria Torres, EAACI President. 'We are entering an era where scientific innovation, equity in care, and environmental health must move forward together.'
The programme featured over 250 hours of lectures, workshops, and symposia, covering groundbreaking advances in drug allergy, T2 inflammation, paediatric asthma, and hereditary angioedema. The Presidential Symposium tackled antimicrobial resistance through a One Health lens, while a timely session on climate change and insect allergy drew global attention to ecological impacts on patient care.
Far beyond the walls of the SEC, the EAACI Congress 2025 activated the entire city with initiatives that brought science to the streets. The Clinical Village at the Glasgow Science Centre welcomed the public for hands-on allergy education, while the Beat Allergy Walk & Run raised funds for the Glasgow Children's Hospital Charity, reinforcing EAACI's commitment to social impact and community engagement.
'The spirit of collaboration we witnessed in Glasgow was extraordinary,' said Prof. André Moreira, EAACI Vice President Congresses. 'This energy is now translating into real-world initiatives and global partnerships.'
The Congress also highlighted EAACI's dedication to mentorship, digital health innovation, and amplifying patient's voices.
The countdown for the EAACI Congress 2026 in Istanbul has officially begun, but you won't have to wait until then to dive back into cutting-edge science. From focused meetings to hands-on courses, EAACI has a packed calendar to keep you inspired all year long. Check out what's coming next at https://eaaci.org.
About EAACI
The European Academy of Allergy and Clinical Immunology (EAACI) is Europe's largest professional association in the field, committed to advancing research and care for those affected by allergic diseases.
Contact: communications@eaaci.org | +41 44 205 55 33
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 days ago
- Globe and Mail
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca's total revenues) rose 18% in the second quarter of 2025, generating $6.3 billion in sales. In the first half of 2025, the Oncology segment generated almost $12 billion in revenues, which rose 16% year over year. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck MRK for Lynparza. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $302 million in the first half of 2025, driven by demand growth in the second-line biomarker-altered population. AstraZeneca expects further growth for Truqap to be driven by increased uptake within the PIK3CA population and additional global launches. AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first half, recording sales of $14 million. Important late-stage oncology candidates in AstraZeneca's pipeline are camizestrant (HR+ HER2- metastatic breast cancer), volrustomig (several types of cancers), sonesitatug vedotin (advanced or metastatic gastric or GEJ adenocarcinoma) and surovatamig (previously untreated follicular lymphoma). Regulatory applications seeking approval of Imfinzi for early-stage gastric and gastroesophageal junction cancers are under regulatory review. AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca's total oncology portfolio suggest a CAGR of around 11.1% over the next three years. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, Merck and Bristol-Myers BMY. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena, and the Braftovi-Mektovi combination. Pfizer's oncology revenues grew 9% in the first half of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics. Merck's key oncology medicines are PD-L1inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Toronto Star
5 days ago
- Toronto Star
EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025
ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to antimicrobial resistance (AMR). A Global Call to Action
National Post
6 days ago
- National Post
Bausch + Lomb to Participate in Upcoming Investor Conferences
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: Article content J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Article content Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Article content Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in investor meetings at the J.P. Morgan conference. Chairman of the Board and Chief Executive Officer Brent Saunders and Sam Eldessouky will participate in a fireside chat at the Morgan Stanley conference. Article content A live webcast of the Morgan Stanley fireside chat will be available on the Investor Relations section of the Bausch + Lomb website. Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Chris Clark Article content Article content Article content Article content (848) 360-1100 Article content Article content Article content
